Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. Tiago M, Purwin TJ, Stefanski CD, et al. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. The Journal of clinical investigation. 2025;135(18). doi:10.1172/JCI178446 Read more